

# JILL T. JOHNSON, PHARM.D., BCPS

August 2017

---

## Work Address:

University of Arkansas for Medical Sciences  
College of Pharmacy, #522-4  
4301 W. Markham Street  
Little Rock, Arkansas 72205

Phone: 501-686-7919  
Cell: 501-831-2386  
Email: [johnsonjillt@uams.edu](mailto:johnsonjillt@uams.edu)  
Alternate email: [johnsonjillt@yahoo.com](mailto:johnsonjillt@yahoo.com)

---

## EDUCATION AND TRAINING

Doctor of Pharmacy Degree: May 1993

University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, Arkansas

ASHP-Accredited Residency Training: July 1993 to June 1994

Pharmacy Practice Residency, Veterans Affairs Medical Center, Little Rock, Arkansas

Pre-Pharmacy Education: August 1986 to May 1989

University of Arkansas, Fayetteville, Arkansas

---

## PROFESSIONAL BOARD CERTIFICATION

NABP Pharmacist Licensure: Arkansas, since 1993

Board Certification in Pharmacotherapy Specialty (BCPS), 1997-2018

Arkansas Collaborative Practice Certification

---

## CURRENT PROFESSIONAL EXPERIENCE

---

|                        |                                                                                                                                                                                   |
|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| July 2015-Present      | Full Professor with Tenure, Department of Pharmacy Practice, University of Arkansas for Medical Sciences, Little Rock, AR                                                         |
| July 1994 - Present    | Interdisciplinary Team Member, General Medicine Service-Team 3A, University Hospital, UAMS, Little Rock, AR<br>Vancomycin Monitoring Service, as part of the service to this team |
| January 2017 – Present | Clinical Pharmacy Consultant, Jill Johnson Consulting LLC, est. January 2017                                                                                                      |
| January 2004 - Present | Clinical Consultant, Arkansas State Employees/Public School Employees, Employee Benefits Division, Formulary Management for Prescription Drug Program                             |
| July 2004 - Present    | Committee Member, University of Arkansas Systems Pharmacy Advisory Committee (UASPAC)                                                                                             |
| May 2016-Present       | Committee Member, Institute for Clinical and Economic Review (ICER) Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), 3 year term                        |
| January 2007 - Present | Board Member, Arkansas Medicaid Drug Utilization Review Board (DUR Board)                                                                                                         |

- June 1999 - Present Voting Member, UAMS Hospital Pharmacy and Therapeutics Committee
- August 2005 - Present Expert Witness:
- August 2017, Expert Witness, Polysubstance case, Woehner Law Firm, Madison, Wisconsin
  - April 2017, Expert Witness, Methotrexate case, Trammell Piazza Law Firm, Little Rock, AR
  - August 2015, Expert Witness, Polysubstance case, Clifford & Raihala, Madison, Wisconsin
  - March 2014, Expert Witness, Opiate case, Calderhead, Lockemeyer & Peschke Law Office, Milford, Ohio
  - March 2014, Expert Witness, Pharmacy Dispensing case, Rodey Law, Albuquerque, New Mexico
  - January 2008-2010, Clopidogrel & Aspirin case, Little Rock, AR
  - April 2007, Expert Witness, Case 1:06-cv-02157-RWR, a class action complaint, Partners of Garwin Gerstein & Fisher LLP, Plaintiff Louisiana Wholesale Drug Co, v. AstraZeneca Pharmaceuticals
  - August 2005-June 2006, Expert Witness, PPI case, Wilkes and McHugh Law Firm, Little Rock, AR

### **PAST PROFESSIONAL EXPERIENCE**

---

- November 2004 - 2016 Voting Member, AR Medicaid Drug Review Committee (Preferred Drug List)
- July 2002 – June 2015 Associate Professor with Tenure, Department of Pharmacy Practice, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR
- July 1994 - June 2002 Assistant Professor, Department of Pharmacy Practice, UAMS, Little Rock, AR
- April 1995 - March 2001 Implementer and Coordinator, UAMS Anticoagulation Clinic, Little Rock, AR
- April 1995 - December 2003 Team Member, UAMS Anticoagulation Clinic, Little Rock, AR
- August 1994 to May 2001 Coumadin Clinic Consultant Pharmacist, VA Medical Center, Little Rock, AR
- July 1994 to 2000 UAMS Consultant Pharmacist, Pharmacokinetic Monitoring Service, Little Rock, AR
- September 1995 to 1997 Relief Pharmacist, Finnegan’s Family Drug Store, Little Rock, AR
- October 1995 to March 1997 Relief Pharmacist, Drug Emporium, Little Rock, AR
- July 1993 to March 1996 Relief Pharmacist, Wal-Mart Pharmacy, Little Rock, AR
- July 1993 to June 1994 Pharmacy Practice Resident, Veterans Affairs Medical Center, Little Rock, AR
- May 1993 to June 1993 Staff Pharmacist, Veterans Affairs Medical Center, Little Rock, AR
- January 1990 to May 1993 Pharmacy Technician, St. Vincent Infirmary Medical Center, Little Rock, AR

### **CURRENT TEACHING**

---

- 1994-Present **PhPr 6714 Clerkship in General Internal Medicine**  
Preceptor, Responsibilities: Rounding with Multidisciplinary General Internal Medicine Team, 2-fourth year pharmacy students per month, ~5-6 months per year
- 2011-Present **Residency Program Director**, PGY1 Managed Care Residency, UAMS
- 2011-Present **PhPr 5643 Evidence-Based Medicine, Biostatistics, Pharmacoeconomics**  
Course Coordinator & Lecturer (Fall 2012-Present),  
Co-Course Coordinator & Lecturer (Fall 2008-11),

Lectures: Introduction to Evidence-based Medicine, EBM Framework/Asking Clinical Questions, Validity of Clinical Trials: Populations, External validity, Exclusion/Inclusion, Study Design: Controlled Trials, Randomization, Allocation Concealment, Blinding, Loss to Follow-up, Trial Results: Analysis by Intention to Treat vs Per Protocol Analysis, Factoring in Baseline Characteristics, Composite endpoints, Flawed Assumptions, Run-ins, Calculating Relative Risks, Number Needed to Treat/Harm; Interpreting Hazard Ratios, Odds Ratios, and 95% Confidence Intervals, Levels of Evidence, Statistical vs Clinical Significance, Practice Guidelines

- 2016-present **Special Problems Elective in EBM**  
Four third-year Pharm.D. Students
- 2010-present **Pharmacy Practice I**  
First-year Pharm.D. Students
- 1995- Present **PhSc 4642 Clinical Pharmacokinetics**  
Heparin, Low Molecular Weight Heparins, Newer Anticoagulants, and Warfarin

#### PAST TEACHING EXPERIENCE

---

- 1994-2012 **PhPr 5635 Therapeutics II and Recitation**  
Course Coordinator (2002-2008)  
Recitation Coordinator (2002-2008)  
Lecturer (1994-2012)  
Recitation Leader (1994-1996)  
Lectures: Deep Vein Thrombosis and Pulmonary Embolus, Fundamentals of Coagulation & Drugs in Anticoagulation, Treatment of Venous Thromboembolism, Prevention of Venous Thromboembolism; Hypercoagulable States, Mechanical and Bioprosthetic Heart Valves, Atrial Fibrillation and Antithrombotic Therapy, Heparin-induced Thrombocytopenia
- 1998-2011 **PhPr 4625 Therapeutics I -Lecturer**  
Ascites and Spontaneous Bacterial Peritonitis, Viral Hepatitis, Management of GI Bleeding, Peptic Ulcer Disease, Gastroesophageal Reflux Disease, Anemia, Sickle cell anemia
- 2003-2013 **Adult Medicine Case Conferences**, Coordinator & Participant
- 2008 **PhPr 5642 Evidence-based Medicine & Pharmacoeconomics**  
Co-Course Coordinator and Developer
- 2005-2008 **PhPr 6614 Indirect Patient Care Experience/ Evidence-based Medicine**  
Co-coordinator and Preceptor
- 1998-2005, 2008 **PhPr 5862 Landmark Trials and Consensus Statements Elective**  
Course Coordinator and Leader
- 2008 **PhPr 5332 Special Problems in Clinical Practice Independent Study Elective**  
Course Coordinator
- 1994-2008 **NTPD 6613 Nontraditional Program Adult Medicine Rotation**  
General Internal Medicine, Acute Care. Preceptor
- 1995-2006 **Pharmacy Practice I** Heart-rate, blood pressure Lab  
Third-year Pharm.D. Students, Small Group Leader
- 1998, 1999, 2003 **Introduction to Patient Monitoring**  
Second-year Pharm.D. Students: Coagulation Laboratory Monitoring
- 1994-1996 **Laboratory Monitoring Elective**  
Third-year Pharm.D. Students: Coagulation Laboratory Monitoring

## Academic Advisement: Postgraduate Programs

- 2013-2014 Pharmacy Practice Pharmaceutical Evaluation and Policy, Graduate thesis committee member. Master's Candidate Praveen Potukuchi. I provided clinical considerations and review for research on association between urinary incontinence and inflammatory conditions.
- 2013-2014 Pharmacy Practice Pharmaceutical Evaluation and Policy, Graduate thesis committee member. Master's Candidate Anand Shewale. I provided clinical considerations and review for research on instruments for assessing stroke risk and bleeding risk in atrial fibrillation patients considered for anticoagulation.

## PEER-REVIEWED PUBLICATIONS

---

### Book contributions, Invited Content:

**Johnson JT.** Evaluating Clinical Literature: An Overview. In: Aparasu RR, Bentley JP, eds. *Principles of Research Design and Drug Literature Evaluation*. 1st Ed. Burlington, MA: Jones & Bartlett Learning; 2014: 274-288.

**Johnson JT.** Clinical Scenario and Clinical Significance: Serotonin Receptors and Drugs Affecting Serotonergic Neurotransmission. Glennon RA, Dukat M. In: Lemke TL, Williams DA, eds. *Foye's Principles of Medicinal Chemistry Seventh Ed.* Philadelphia: Lippincott Williams & Wilkins; 2013: 366, 367, 392-3.

**Johnson JT.** Clinical Scenario and Clinical Significance: Central Analgesics. Williams DA, Roche VF, Roche EB. In: Lemke TL, Williams DA, eds. *Foye's Principles of Medicinal Chemistry Seventh Ed.* Philadelphia: Lippincott Williams & Wilkins; 2013: 659, 694.

**Johnson JT.** Clinical Scenario and Clinical Significance: Nonsteroidal Anti-Inflammatory Drugs. Borne R, Levi M, Wilson N. In: Lemke TL, Williams DA, eds. *Foye's Principles of Medicinal Chemistry Seventh Ed.* Philadelphia: Lippincott Williams & Wilkins; 2013: 987, 990, 1040-41.

**Johnson JT.** Clinical Scenario and Clinical Significance: Serotonin Receptors and Drugs Affecting Serotonergic Neurotransmission. Glennon RA, Dukat M. In: Lemke TL, Williams DA, eds. *Foye's Principles of Medicinal Chemistry Sixth Ed.* Philadelphia: Lippincott Williams & Wilkins; 2008: 418.

**Johnson JT.** Clinical Scenario and Clinical Significance: Opioid Analgesics. Fries DS. In: Lemke TL, Williams DA, eds. *Foye's Principles of Medicinal Chemistry Sixth Ed.* Philadelphia: Lippincott Williams & Wilkins; 2008: 652.

**Johnson JT.** Clinical Scenario and Clinical Significance: Nonsteroidal Anti-Inflammatory Drugs. Borne R, Levi M, Wilson N. In: Lemke TL, Williams DA, eds. *Foye's Principles of Medicinal Chemistry Sixth Ed.* Philadelphia: Lippincott Williams & Wilkins; 2008: 954.

### Journal articles:

Shewale AR, **Johnson JT**, Li C, Nelsen D, Martin BC. Net clinical benefits of guidelines and decision tool recommendations for oral anticoagulant use among patients with atrial fibrillation. *J Stroke Cerebrovasdis.* 2015;24(12).

Shewale A, **Johnson J**, Li C, Nelsen D, Martin B. Variation in anticoagulant recommendations by the guidelines and decision tools among patients with atrial fibrillation. *Healthcare*. 2015;3(1):130-145.

Dayer LE, Hutchins LF, **Johnson JT**. Treatment of metastatic melanoma with pazopanib: a report of five patient cases. *Journal of Oncology Pharmacy Practice*. 2014. Online first:  
<http://opp.sagepub.com/content/early/2014/02/27/1078155214524084>

Kaye CJ, Neill KK, Davis D, **Johnson JT**. Statin Cost and Utilization Outcomes after Implementation of Reference-based Pricing. *Am J Pharm Benefits*. 2013;5(1):e8-e14.

Neill KK, **Johnson JT**. An Advanced Pharmacy Practice Experience in Application of Evidence-based Policy. *American Journal of Pharmaceutical Education*. 2012;76(7) article 133.

**Johnson JT**, Neill, KK, Davis D. Five-Year Examination of Utilization and Drug Cost Outcomes Associated with Benefit Design Changes Including Reference Pricing for Proton Pump Inhibitors in a State Employee Health Plan. *J Manag Care Pharm*. 2011;17(3):200-12. April 2011. \*nominated for the JMCP Award for Excellence, 2011.

Vanderbush RE, **Johnson JT**, Hutchison LC, West DS. Use of an Audience Response System in Continuing Education. 2006. *AJPE*;70(3), Abstract 65.

West DS, **Johnson JT**, Hong SH. A 30-month evaluation of the effects on the cost and utilization of proton pump inhibitors from adding omeprazole OTC to drug benefit coverage in a state employee health plan. *J Manag Care Pharm*. 2006;12(1):25-32. \*nominated for the JMCP Award for Excellence. 2006.

**Johnson JT**, West DS. Using an Evidence-based Medicine Approach to Reduce costs for Proton-Pump Inhibitors in a State Employee Health Plan. *Drug Benefit Trends*. 2005;17(9):393-401.

Harris BN, West DS, **Johnson J**, Hong SH, Stowe C. Effects on the Cost and Utilization of Proton Pump Inhibitors from Adding OTC Omeprazole to Drug Benefit Coverage in a State Employee Health Plan. *J Man Care Pharmacy*. 2004;10(5):449-550. \*Nominated for Best Paper in JMCP 2004

**Johnson JT**, Stowe CD, Savidge MA, Gardner SF. Enhancing the Quantity and Quality of Student Comments on Teaching Assessment Tools. *Journal of Pharmacy Teaching*. 2004;11(1):41-56.

**Johnson JT**. Venous Thromboembolism Prophylaxis in the Medically Ill. ARDONA Report. 2003;4(1):3-4.

Granberry MC, **Johnson JT**, Myatt S, et al. Comparison of Evidence-Based Medicine Knowledge between Physician Faculty, Physician Residents and Pharmaceutical Industry Representatives. Abstract 11/02.

**Johnson JT**, Granberry MC, Thomas AR. Anticoagulation Management in Mechanical Heart Valve Patients who Undergo Dental Procedures. *J AR Med Society*. 2000;97(4):128-31.

Schneider EF, Gardner S, **Johnson JT**. Development of a Practical Examination Utilizing Standardized participants for Disease State Management Credentialing. *AmJPhEd*. 2000;64:173-75.

**Johnson JT**, Dunn EB, Wolfe JJ. Two antiretroviral drugs likely to be confused. *Am J Health-Syst Pharm*. 1998;55:1728.

Granberry MC, **Johnson JT**, Stafford AD, Carthan N. Implementation and evaluation of patient case-based discussion of optimal therapy derived from landmark studies and consensus statements. *AJPE*. 1998;62:110s.

DFCM-Pharmacy Group: Coulter L, Grady A, Granberry M, Geurian K, **Johnson J**, Marsh C, McCafferty R, Myatt SM, Schneider E. Case-based lecture versus standard lecture style. *AJPE*.

## PRESENTATIONS (since year 2000)

---

### INTERNATIONAL

---

- Poster Presentation: Shewale AR, Nelsen DA, **Johnson JT**, Li C, Martin B. Comparison of the guidelines and decision tool recommendations for oral anticoagulant use among patients with atrial fibrillation. University of Arkansas for Medical Sciences, AR, USA. Accepted to ISPOR 19th Annual International Meeting. May 31 - June 4, 2014, at Palais des Congrès de Montréal, Montreal, QC, Canada.
- Poster Presentation: Shewale AR, Nelsen DA, **Johnson JT**, Li C, Martin B. Comparison of decision support tools and guidelines used to guide anticoagulation therapy for patients with nonvalvular atrial fibrillation. University of Arkansas for Medical Sciences, AR, USA. Accepted to ISPOR 19th Annual International Meeting. May 31 - June 4, 2014, at Palais des Congrès de Montréal, Montreal, QC, Canada.
- Poster Presentation: Potukuchi PK, **Johnson JT**, Martin B, Hutchison LC, Bursac Z, Said Q. Treatment patterns of urinary incontinence in the presence of comorbidities. University of Arkansas for Medical Sciences, AR, USA. Accepted to ISPOR 19th Annual International Meeting. May 31 - June 4, 2014, at Palais des Congrès de Montréal, Montreal, QC, Canada.
- Poster Presentation: Potukuchi PK, **Johnson JT**, Martin B, Hutchison LC, Bursac Z, Said Q. Impact of arthritis and other comorbidities on incidence of urinary incontinence: a case control study. University of Arkansas for Medical Sciences, AR, USA. Accepted to ISPOR 19th Annual International Meeting. May 31 - June 4, 2014, at Palais des Congrès de Montréal, Montreal, QC, Canada.

### NATIONAL

---

- Poster Presentation: Mullings A, **Johnson JT**. Cost and Utilization Outcomes of Antivirals Used in the Treatment of Herpes Labialis After Exclusion of Topical Antivirals in a Self-Funded Managed Care Plan. AMCP Managed Care & Specialty Pharmacy Annual Meeting, San Francisco, CA, April 20, 2016.
- Poster Presentation: Shewale AR, Nelsen DA, **Johnson JT**, Li C, Martin BC. Net clinical benefit of the 2014 AHA/ACC/HRS Guideline used to guide anticoagulation therapy for patients with nonvalvular atrial fibrillation. Southern Pharmacy Administration Conference (SpAC) Oklahoma City, OK, June 20-22, 2014. Submitted.
- Poster Presentation: Dayer LE, Merrell KS, **Johnson JT**, Hutchins LF. Treatment of metastatic melanoma with pazopanib: a report of 5 patient cases. Presented at American Society of Health-Systems Pharmacists (ASHP) Midyear Clinical Meeting, Orlando, FL, December 8-12, 2013. (Poster #1-039)
- Poster Presentation: Kaye C, Davis DA, Neill KK, **Johnson J**. Statin Cost & Utilization Outcomes After Implementation of Reference-based Pricing. Presented at the 24<sup>th</sup> Annual Academy of Managed Care Pharmacy Meeting, San Francisco, CA. April 2012.
- Poster Presentation: Neill K, Warmack S, **Johnson J**, Gubbins P, Schneider E, Carle M. Implementation of a Faculty Item Review Process for Examination Content in the Therapeutics Coursework. Presented at the Annual Meeting of the American Association of Colleges of Pharmacy, Seattle, WA. July 2010; *AJPE* 2010;74(5) Article 96.
- National Webcast for Pharmacy Benefit Managers Institute. **Johnson JT** and Dickerson S. Arkansas State Employee Benefits Division. Prilosec OTC Program. November 8, 2006.
- Poster Presentation: Neill KK, **Johnson JT**, Gubbins PO. An Experience in Evidence-Based Policy Application

(School Poster). 2005 American Association of Colleges of Pharmacy Annual Meeting and Seminars. Cincinnati, Ohio (July 2005);AJPE 2005;69(3) Article 60.

- **Johnson JT.** Aligning Payer, Pharmacy, and Beneficiary Interests, Pharmacy Benefit Management Institute Annual Conference, Scottsdale, AZ, March 30, 2005.
- Poster Presentation: Granberry MC, **Johnson JT**, Myatt S, McAfferty R, Sabbe J, Warmack S, Smith ES. Comparison of evidence-based medicine knowledge among physician faculty physician residents and pharmaceutical industry representatives. American College of Clinical Pharmacy, Palm Springs, CA, April 28, 2003.

#### STATE

---

- Bemberg GB, **Johnson JT.** Accessibility of Information Concerning the Ramifications of Drug Coupons (Poster). Presented at Arkansas Association of Health Systems Pharmacy Fall Seminar, Little Rock. October 2014.
- Dayer LE, Merrell KS, **Johnson JT**, Hutchins LF. Treatment of metastatic melanoma with pazopanib: a report of 5 patient cases. Presented at Arkansas Association of Health Systems Pharmacy Fall Seminar, Little Rock, AR, October 2013.
- Brazeal J, **Johnson JT**, Neill KK. Development of an Evidence-based Prior Authorization Pathway for Colony-Stimulating Factors. Presented at Arkansas Association of Health Systems Pharmacy Fall Seminar, Hot Springs, AR, October 2012.
- **Johnson JT.** “Roflumilast”. AR Medicaid Drug Utilization Review Board. Oct. 19, 2011.
- **Johnson JT.** “Newer Diabetes Drugs”. Arkansas State Employees Drug Utilization and Evaluation Committee. February 8, 2011.
- Neill KK, Fielder B, **Johnson JT.** Implementation of a Reference Pricing Strategy for Proton Pump Inhibitors in a State Employees Prescription Drug Plan (Poster). Presented at Arkansas Association of Health Systems Pharmacy Fall Seminar, Little Rock. October 2009.
- **Johnson JT.** Methadone: Do’s, Don’ts, and Dosing. College of Pharmacy CE Program-1hour, Little Rock, AR, October 18, 2009. ACPE Program No. 004-000-09-037-L01-P.
- Neill KK, Fielder B, **Johnson JT.** Six Month Follow-Up for Implementation of Formulary Revisions for Atorvastatin 80 mg Prescriptions (Poster). Presented at Arkansas Association of Health System Pharmacy Fall Seminar, Tunica, MS. October 10, 2008.  
\*\*\*Arkansas Association of Health-System Pharmacists Fall Seminar Best Poster Award
- Neill KK, Fielder B, **Johnson JT.** The Impact of Implementation of Prior Authorization Criteria for omalizumab (Xolair<sup>®</sup>) in a State Employees Prescription Drug Plan (Poster). Presented at Arkansas Association of Health System Pharmacy Fall Seminar, Tunica, MS. October 10, 2008.
- **Johnson JT** Area Health Education Center (AHEC) Pine Bluff, “Evidence-based Medicine & Interpreting Therapy Articles”, Medical Resident and Staff Noon Conference, February 5, 2008.
- **Johnson JT.** “No Free Lunch, Just Say ‘No’”, College of Pharmacy CE Program-1hour, Alumni Weekend, Little Rock, AR, October 2006. ACPE Program No. 004-000-06-039L04.
- **Johnson JT.** Antithrombotic Guidelines Update from the American College of Chest Physicians, UAMS College of Pharmacy CE Program-1hour, Destin, FL, August 2005.
- **Johnson JT.** Evidence-based Medicine, UAMS College of Pharmacy CE Program 2-hours, Destin, FL, August 2005.
- **Johnson JT.** Anticoagulation: New and Old, Arkansas Association of Hospital Pharmacists, Annual Meeting, June 10, 2004.

## LOCAL

---

- **Johnson JT.** Anticoagulants-The Old and the New. December 4, 2011. ACPE accredited, 0004-0000-11-061-L01-P.
- **Johnson JT.** UAMS College of Pharmacy Residency Teaching Certificate Program, “Evidence-based Medicine”, July 23, 2008.
- **Johnson JT.** UAMS Family Medical Center, Noon Conference, “EBM”, July 9, 2008.
- **Johnson JT.** UAMS College of Pharmacy Seminar, “There’s No Free Lunch: Promoting Healthy Skepticism”, September 7, 2007.
- **Johnson JT.** PBM, PPO, and EBM: Alphabet Soup in Today’s Pharmacy Environment, May 23, 2005. ACPE Program No.004-000-05-031-L01.
- **Johnson JT.** PPI’s: what the Hospital pharmacist Needs to Know, UAMS College of Pharmacy CE Program, October 28, 2004, ACPE Program No.004-000-04-032-L01.
- **Johnson JT.** Anticoagulant Pharmacology, Grand Rounds for Cardiology and Cardiovascular Surgery, November 2003.
- **Johnson JT.** Update on Post-Menopausal Osteoporosis, UAMS Learn @ Noon Conference, November 5, 2002, and for Arkansas Pharmacists CE on November 10, 2002. ACPE Program No. 004-000-02-015-L01
- **Johnson JT.** Issues Related to DVT Prophylaxis in Long-Term Care Patients: Opportunities to Prevent VTE, for the Donald W. Reynolds Center on Aging, sponsored by the UAMS College of Pharmacy and the Arkansas Pharmaceutical Association’s Academy of Consultant Pharmacists, October 20, 2002. ACPE Program No. 004-000-02-012-L-01.
- **Johnson JT .** Issues Related to DVT Prophylaxis in Long-Term Care Patients: Missed Opportunities to Prevent VTE, Local Consultant Panel Sponsored by Aventis Pharmaceuticals, August 9, 2002.
- **Johnson JT** Increased Student Participation in the Evaluation of Faculty in a Team-taught Course, UAMS Teaching Scholars, February 20, 2001.
- **Johnson JT** Gastrointestinal Drugs, UAMS Graduate Nursing Course, 3 hours, Fall & Spring 1996-2001.
- **Johnson JT** Polycystic Ovary Syndrome, ACPE Program No. 177-000-00-.004-L01, Continuing Education for Pharmacists, One hour, June 8, 2000, Arkansas Pharmacists Association.

## EDITORIAL REVIEW

---

2016 Pharmacotherapy Preparatory Review and Recertification Course, Study Designs chapter, Dec 2015.

- Textbook Chapter 10: Venous Thromboembolism. Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, eds. Pharmacotherapy Principles & Practice, 3<sup>rd</sup> edition, 2013.
- Textbook Chapter: Ch. 7 Venous Thromboembolism. Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, eds. Pharmacotherapy Principles & Practice, 2nd edition, 2010.
- ASHP PharmPrep Reviewer. Anemia Chapter. September 2010.
- Systematic review of the cost-effectiveness of BIPHASIC INSULIN ASPART 30 IN TYPE 2 DIABETES. Current Medical Research & Opinion. Dec 2009.
- 2009 PSAP Reviewer for Anemias in the Chronic Illnesses Chapter.
- Textbook Chapter: Ch. 7 Venous Thromboembolism. Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, eds. Pharmacotherapy Principles & Practice, 1<sup>st</sup> edition, 2008.
- American Journal of Pharmacy Benefits
- Journal of Managed Care Pharmacy
- Annals of Pharmacotherapy



## RESEARCH INVOLVEMENT

---

- Co-Investigator; Pilot Evaluation of an Audience Response System in a Pharmacist Continuing Education Meeting. Vanderbush R, **Johnson JT**, Hutchison L, West DS., Completed 8/05.
- Study Coordinator and Sub-Investigator; A Double-Blind, Placebo-Controlled, Parallel, Multicenter Study on Extended VTE Prophylaxis in Acutely Ill Medical Patients With Prolonged Immobilization (EXCLAIM), \$113,500 from Aventis, UAMS, Little Rock, Arkansas, Rob Lavender, M.D., **Jill Johnson, Pharm.D.** closed 8/05.
- Study Coordinator; Efficacy and Safety Study of the Oral Direct Thrombin Inhibitor H376/95 Compared with Dose-Adjusted Warfarin (Coumadin®) in the Prevention of Stroke and Systemic Embolic Events in Patients with Atrial Fibrillation (SPORTIF V), \$46,000 from Astra-Zeneca. UAMS, Little Rock, Arkansas, Eugene Smith, M.D., **Jill Johnson, Pharm.D.** closed.
- A Retrospective Chart Review to compare anticoagulated atrial fibrillation patients in a private clinic vs. a university clinic's anticoagulation monitoring service. UAMS, Little Rock, Arkansas, ended.
- Improvement of Students' Assessment of Faculty in a Team Taught Course, Teaching Scholars Formal Proposal. UAMS College of Pharmacy. Fall 1999-Spring 2000.
- Study Coordinator; Challenge Study: A Multi-Center, Open-Label Study of Atorvastatin 10mg or 80mg or Simvastatin 20mg or 80mg in the Treatment of Patients with Hypercholesterolemia, \$69,000 from Parke-Davis. UAMS, Little Rock, Arkansas, 1998-1999.
- Residency Project: An Open-Label Study of Fluvastatin in the Treatment of Patients with Hypercholesterolemia in Clinical Practice Settings, \$7200. Veterans Affairs Medical Center, Little Rock, Arkansas, 1993-1994.

## SERVICE

---

### NATIONAL (current in BOLD)

---

- **Institute for Clinical and Economic Review Midwest Comparative Effectiveness Public Advisory Council (ICER Midwest CEPAC), 2016-2018**
- **National Association of Boards of Pharmacy Naplex Item Writing Committee Member, 2017**
- National Association of Boards of Pharmacy (NABP) Disease State Management-Anticoagulation Review Committee, 1999-2005
- NABP Disease State Management-Anticoagulation Exam Item-writing Facilitator, 2002
- Board of Pharmaceutical Specialties Internal Medicine Item-writing Committee, 1999
- NABP Disease State Management-Anticoagulation Exam Item-writing Committee, 1998
- NABP Disease State Management-Anticoagulation Exam Passing Standard Committee, 1998

### STATE/REGIONAL (current in BOLD)

---

- **Arkansas Medicaid Drug Utilization Review Board, Feb 2003 to Dec 2004, Jan 2007-present**
- **Arkansas State Employees' Benefits Consultant, Jan 2004 to present**
- **Arkansas State Employees' Delivery Coordination Working Group, a subcommittee to the Drug Use and Evaluation Committee, 2013-present**
- **Pharmacy Advisory Committee Member, (large insurer in AR and beyond), 2016-present**
- Arkansas State Medicaid Drug Review Committee for the Arkansas Medicaid Evidence-based Prescription Drug

- Program, Nov 2004-May 2005, June 2005-Nov 2005, May 2006-Nov 2006, Jan 2010-June 2016
- Pharmacy & Therapeutics Voting Member, (large insurer in AR and beyond), 2014
  - Arkansas Department of Health (ADH) Viral Hepatitis Epidemiologic Profile Stakeholder, April 2014
  - Arkansas State Employees' Benefits Division, Ad Hoc Member, RFP Proposal Evaluation Team for Pharmacy Benefits Audit, June 2007
  - Mid-South College of Clinical Pharmacy Pharmacotherapy Exam Scholarship Committee, 1998

#### UNIVERSITY

---

- **University Hospital Pharmacy and Therapeutics Committee, Voting Member, 1999 to present**
  - Subcommittee on Formulary Limits, 2010
  - Subcommittee on Statin Therapeutic Interchange 5/2006
- **University of Arkansas System Pharmacy Advisory Committee, 2004 to present**
  - RFP Team for PBM selection 2009
  - RFP Team for Pharmacy Consultant selection 2008
  - RFP Team for PBM selection 2006
- Faculty Life Cycle Committee, 2014
- Academic Services Advisory Committee, 2008-2010
- Teaching Scholar 1998-2001
- Ad Hoc Committee Member for the Expansion of the UAMS Anticoagulation Clinic, 1999

#### COLLEGE

---

- **Promotion and Tenure Committee, 2y term: 2016-2018 (Chair 2017), 2014-2016 (Chair 2015, 2016), 2012-2014 Member, 2010-2012 Member, 2007-2008 Alternate, 2005-2007 Member, 2002-2004 Member**
- **Evidence-based Prescription Drug Program Pharmacy & Therapeutics Committee, (Chair) 2012-present**
- **Residency Review Committee, Member, Ad Hoc Committee in Pharmacy Practice, 2014-2016, 2016-2018**
- **Special Accommodations Committee, 2016**
- **Search Committee for Division Head, Pharmaceutical Evaluation & Policy (PEP), 2016**
- MICU Candidate Search Committee, (Chair 2014)
- COP *ad hoc* Special Test Taking Accommodations Committee, 2007-2010
- Student-Faculty Affairs Committee, 2 year term: 2005-2007, 2007-2009
- Undergraduate Admissions Committee, 2 year term: 1997-2000, 2009
- Leadership Team, ACPE Standards for Self-Study Committee 2006-2007
- Scholastic Standing Committee, Chair, 2002-2003
- Faculty Assessment Committee, 1999
- Ad Hoc Committee Member for Non-tenure track Faculty 1998
- UAMS Student Awards Committee 1995, 1996
- Pharmacy Documentation Committee 1996

**References upon request**